Detalhe da pesquisa
1.
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
Blood
; 142(1): 62-72, 2023 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36796019
2.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(2): 282-296, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30665869
3.
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.
Liver Int
; 39(12): 2214-2229, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31436873
4.
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.
Br J Cancer
; 119(1): 19-26, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29808014
5.
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 16(7): 859-70, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26095784
6.
Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.
J Patient Rep Outcomes
; 8(1): 8, 2024 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38252198
7.
Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study.
Clin Lymphoma Myeloma Leuk
; 23(1): 57-67, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335022
8.
Sec61ß controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.
Mol Pharmacol
; 82(3): 510-20, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22710939
9.
Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study.
Adv Hematol
; 2022: 8262787, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36620778
10.
Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.
Mol Pharmacol
; 79(1): 157-66, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20930109
11.
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.
JHEP Rep
; 3(2): 100215, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33392490
12.
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
Curr Med Res Opin
; 37(10): 1769-1778, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34229554
13.
Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.
Mol Pharmacol
; 77(6): 912-21, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20194531
14.
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.
ESMO Open
; 5(4)2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32817068
15.
The Role of Angiogenesis in Hepatocellular Carcinoma.
Clin Cancer Res
; 25(3): 912-920, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30274981
16.
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Eur J Cancer
; 81: 17-25, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28591675
17.
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score.
JAMA Oncol
; 3(2): 235-243, 2017 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27657674
18.
Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis.
Oncotarget
; 7(46): 75482-75491, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27776351
19.
Tracheoesophageal Fistula in a Patient With Advanced NSCLC Who Received Chemoradiotherapy and Ramucirumab.
J Thorac Oncol
; 14(1): e19, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30579552
20.
Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells.
PLoS One
; 9(1): e87444, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24475288